Editas Medicine (EDIT) Tops Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. AMD

Go back to Editas Medicine (EDIT) Tops Q2 EPS by 2c

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

August 4, 2021 7:00 AM EDT

Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10

EDIT-101 initial clinical data planned for September 2021

EDIT-301 RUBY trial for sickle cell disease screening patients; first patient on track to be dosed by year-end

Strengthened leadership with appointment of Chi Li as Chief Regulatory Officer and Bruce Eaton as Chief Business Officer

CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported... More